Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis

Bos JL . ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682–4689.

Balmain A, Pragnell IB . Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature 1983; 303: 72–74.

You M, Candrian U, Maronpot RR, Stoner GD, Anderson MW . Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA 1989; 86: 3070–3074.

To MD, Wong CE, Karnezis AN, Del Rosario R, Di Lauro R, Balmain A . Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet 2008; 40: 1240–1244.

Manenti G, Trincucci G, Pettinicchio A, Amendola E, Scarfo M, Dragani TA . Cis-acting genomic elements of the Pas1 locus control Kras mutability in lung tumors. Oncogene 2008; 27: 5753–5758.

Bremner R, Balmain A . Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 1990; 61: 407–417.

Buchmann A, Ruggeri B, Klein-Szanto AJ, Balmain A . Progression of squamous carcinoma cells to spindle carcinomas of mouse skin is associated with an imbalance of H-ras alleles on chromosome 7. Cancer Res 1991; 51: 4097–4101.

Modrek B, Ge L, Pandita A, Lin E, Mohan S, Yue P et al. Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res 2009; 7: 1244–1252.

Sweet-Cordero A, Tseng GC, You H, Douglass M, Huey B, Albertson D et al. Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes Cancer 2006; 45: 338–348.

To MD, Quigley DA, Mao JH, Del Rosario R, Hsu J, Hodgson G et al. Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer. Mol Cancer Res 2011; 9: 1339–1345.

Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, Li J et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 2001; 29: 25–33.

To MD, Perez-Losada J, Mao JH, Hsu J, Jacks T, Balmain A . A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet 2006; 38: 926–930.

Diaz R, Lue J, Mathews J, Yoon A, Ahn D, Garcia-Espana A et al. Inhibition of Ras oncogenic activity by Ras protooncogenes. Int J Cancer 2005; 113: 241–248.

Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, Schmitt E et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 1997; 11: 2468–2481.

Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243–3248.

Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004; 5: 375–387.

Ise K, Nakamura K, Nakao K, Shimizu S, Harada H, Ichise T et al. Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene 2000; 19: 2951–2956.

Nagase H, Bryson S, Cordell H, Kemp CJ, Fee F, Balmain A . Distinct genetic loci control development of benign and malignant skin tumours in mice. Nat Genet 1995; 10: 424–429.

Hager JH, Hodgson JG, Fridlyand J, Hariono S, Gray JW, Hanahan D . Oncogene expression and genetic background influence the frequency of DNA copy number abnormalities in mouse pancreatic islet cell carcinomas. Cancer Res 2004; 64: 2406–2410.

Dworkin AM, Ridd K, Bautista D, Allain DC, Iwenofu OH, Roy R et al. Germline variation controls the architecture of somatic alterations in tumors. PLoS Genet 2010; 6: e1001136.

Hennings H, Glick AB, Lowry DT, Krsmanovic LS, Sly LM, Yuspa SH . FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin. Carcinogenesis 1993; 14: 2353–2358.

Perez-Losada J, Balmain A . Stem-cell hierarchy in skin cancer. Nat Rev Cancer 2003; 3: 434–443.

Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A et al. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996; 86: 531–542.

Diaz R, Ahn D, Lopez-Barcons L, Malumbres M, Perez de Castro I, Lue J et al. The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res 2002; 62: 4514–4518.

Quinlan MP, Settleman J . Explaining the preponderance of Kras mutations in human cancer: an isoform-specific function in stem cell expansion. Cell Cycle 2008; 7: 1332–1335.

Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410: 1111–1116.

Lee KE, Bar-Sagi D . Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell 2010; 18: 448–458.

Mao JH, To MD, Perez-Losada J, Wu D, Del Rosario R, Balmain A . Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression. Genes Dev 2004; 18: 1800–1805.

Nagase H, Mao JH, Balmain A . Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice. Cancer Res 2003; 63: 4849–4853.